Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01276210
Other study ID # VICC RAD1060
Secondary ID NCI-2010-02407
Status Completed
Phase Phase 1
First received January 11, 2011
Last updated July 14, 2017
Start date February 2011
Est. completion date June 2017

Study information

Verified date July 2017
Source Vanderbilt-Ingram Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. Stereotactic radiosurgery (SRS) may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Giving sorafenib tosylate together with SRS may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and the best dose of sorafenib tosylate when given together with SRS in treating patients with brain metastases


Description:

PRIMARY OBJECTIVES:

I. To determine the safety, tolerability and maximum tolerated dose (MTD) of sorafenib, when administered in combination with SRS to patients with 1-4 metastatic brain tumors.

SECONDARY OBJECTIVES:

I. To assess the six-month intra-cranial progression-free survival (PFS) of sorafenib when administered in combination with SRS to patients with 1-4 metastatic brain tumors. PFS is defined as the time to intra-cranial tumor progression or death.

II. To assess the six-month overall survival (OS) of sorafenib when administered in combination with SRS to patients with 1-4 metastatic brain tumors.

III. To compare results to patients who are treated with SRS alone (concurrent controls).

OUTLINE: This is a dose-escalation study of sorafenib tosylate.

Patients receive oral (PO) sorafenib tosylate once daily and undergo SRS 5-7 days later. Treatment with sorafenib continues for 2 weeks after SRS in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 8, 26, and 52 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date June 2017
Est. primary completion date July 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically confirmed cancer with 1-4 brain metastases (except lymphoma or small cell histologies)

- ECOG PS 0 or 1

- Patients are candidates for stereotactic radiosurgery as determined by the treating radiation oncologist. Intra-cranial tumors must measure 4cm or less in greatest dimension. Patients may have received prior neurosurgical resection(s) of intra-cranial metastases if their operation(s) was (were) completed at least 6 months prior to study enrollment. Patients may have had prior whole brain radiation therapy (WBRT) if it was completed at least 6 months prior to study enrollment.

- Age = 18 years and willing and able to sign a written informed consent; a signed informed consent must be obtained prior to any study specific procedures

- INR < 1.5 or a PT/PTT within normal limits; patients receiving anti-coagulation treatment with an agent such as warfarin or heparin may be allowed to participate; for patients on warfarin, the INR should be measured prior to initiation of sorafenib and monitored at least weekly (INR must be therapeutic in the range of 2-3)

Subjects must receive 1st dose of sorafenib 5-7 days prior to administration of Stereotactic Radiosurgery.

Exclusion Criteria:

- Congestive heart failure > class II NYHA; patients must not have unstable angina (anginal symptoms at rest) or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months

- Unable to undergo brain MRI

- CNS metastases from lymphoma or small cell lung cancer

- Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy

- Uncontrolled hypertension defined as systolic blood pressure > 140mm Hg or diastolic pressure > 90 mm Hg, despite optimal medical management

- Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C

- Active clinically serious infection > CTCAE v 4.0 Grade 2

- Thrombolic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months

- Pulmonary hemorrhage/bleeding event >= CTCAE v 3.0 Grade 2 within 4 weeks of first dose of study drug

- Any other hemorrhage/bleeding event >= CTCAE v 3.0 Grade 3 within 4 weeks of first dose of study drug

- Serious non-healing wound, ulcer, or bone fracture

- Any drug that results in hepatic enzyme induction such as anti-convulsants (dilantin, depakote, tegretol, phenobarbital); keppra is allowed

- Evidence or history of bleeding diathesis or coagulopathy

- Any pulmonary hemorrhage CTCAE v 4.0 Grade 2 or higher within 4 weeks of first study drug

- Any other bleeding or hemorrhage CTCAE v 4.0 Grade 3 or higher within 4 weeks of first drug

- Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug

- Use of St. John's Wort or rifampin (rifampicin) within the last 8 weeks

- Known or suspected allergy to sorafenib

- Any condition that impairs patient's ability to swallow whole pills

- Concurrent investigational drugs

- Concurrent steroids are allowed if Dexamethasone dose is =< 16mg daily; if feasible, steroids should be weaned off once sorafenib has been initiated

- Prior therapy with sorafenib or other tyrosine kinase inhibitors within the last 12 months; patients are allowed to have been on prior bevacizumab therapy as long as it was stopped at least 6-8 weeks prior to enrolling on this trial

- Any malabsorption problem

- Hemoglobin =< 9.0 g/dl

- Absolute neutrophil count (ANC) =< 1,500/mm^3

- Platelet count =< 100,000/mm^3

- Total bilirubin >= 1.5 times upper limit of normal (ULN)

- ALT and AST >= 2.5 times the ULN ( =< 5 x ULN for patients with liver involvement)

- Creatinine >= 1.5 times ULN

- Women of childbearing potential with a positive serum pregnancy test performed within 7 days prior to the start of treatment; women and men of childbearing potential that do not agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation; men who do not agree to use adequate birth control for at least three months after the last administration of sorafenib

- All toxicities from prior therapies must have resolved to CTCAE v3.0 Grade I or better by the time of study enrollment

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
sorafenib tosylate
Given PO
Radiation:
stereotactic radiosurgery
Undergo stereotactic radiosurgery
Other:
laboratory biomarker analysis
Correlative studies

Locations

Country Name City State
United States Vanderbilt-Ingram Cancer Center Nashville Tennessee

Sponsors (2)

Lead Sponsor Collaborator
Vanderbilt-Ingram Cancer Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The maximum tolerated dose (MTD) of combining sorafenib with SRS At 1 month
Secondary Intra-cranial progression-free survival (PFS) At 6 months
Secondary Overall survival(OS) in study patient population at 6 months
See also
  Status Clinical Trial Phase
Completed NCT02107755 - Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma Phase 2
Terminated NCT01217411 - RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer Phase 1
Completed NCT00098605 - Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases Phase 2
Completed NCT00072163 - Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma Phase 2
Completed NCT01703507 - Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Phase 1
Completed NCT00033254 - Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases Phase 3
Active, not recruiting NCT01706432 - Hypofractionated Image Guided Radiation Therapy in Treating Patients With Stage IV Breast Cancer
Recruiting NCT01891318 - Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study Phase 1/Phase 2
Suspended NCT01843413 - Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases N/A
Completed NCT01234740 - Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases Phase 1
Completed NCT02312622 - Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer Phase 2
Terminated NCT00937482 - Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer Phase 1
Terminated NCT02269111 - Quantitative MRI in Assessing Disease in Patients With Brain Tumors N/A
Withdrawn NCT02277561 - Voxel Based Diffusion Tensor Imaging in Predicting Response in Patients With Brain Metastases Undergoing Whole Brain Radiation Therapy or Stereotactic Radiosurgery N/A
Completed NCT00992602 - Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer Phase 2
Withdrawn NCT02145910 - Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases Phase 1